Atossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenue
Reuters2026/08/07 12:32- Atossa Therapeutics posted a GAAP net loss of USD 18.1 million for the six months ended June 30, 2026, using USD 19.23 million in operating cash flow.
- Operating expenses fell 3.33% to USD 8.7 million for the quarter, while they rose 12.73% to USD 18.6 million for the first half.
- R&D spending slipped 11% to USD 4.9 million for the quarter, while it was flat at USD 9.68 million for the first half.
- G&A expense rose 7% to USD 3.8 million for the quarter, climbing 31% to USD 8.89 million for the first half on higher legal fees.
- Cash and cash equivalents were USD 26.1 million at June 30, 2026; the company raised USD 4 million net in a June registered direct offering.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.

Dogecoin ETF Closure Sets October Exit for Bitwise BWOW Holders
